𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease

✍ Scribed by Zelber–Sagi, Shira; Kessler, Ada; Brazowsky, Eli; Webb, Muriel; Lurie, Yoav; Santo, Moshe; Leshno, Moshe; Blendis, Laurence; Halpern, Zamir; Oren, Ran

Book ID
120929536
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
309 KB
Volume
4
Category
Article
ISSN
1542-3565

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Betaine for nonalcoholic fatty liver dis
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Correction: Betaine for nonalcoholic fat
Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 2 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.